![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BioWa and Medarex Announce Expansion of Licensing Agreement
BioWa and Medarex Announce Expansion of Licensing Agreement
May 24, 2005
BioWa, Inc. and Medarex, Inc. announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent Technology for the enhancement of antibody-dependent cellular cytotoxicity (ADCC). Medarex plans to use the Potelligent Technology to enhance the ADCC function of selected Medarex antibodies for potential therapeutic applications, including cancer. The agreement provides Medarex with nonexclusive commercial rights to develop antibodies for an undisclosed number of targets.
()a href="http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-24-2005/0003685104&EDATE=" target="_blank">PR Newswire
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct